Related Experiment Videos
A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase
H Kawakatsu1, T Sakai, Y Takagaki
1Molecular Biology Department, Research Laboratories, Nippon Shinyaku Co. Ltd., 601 Kyoto, Japan.
Abstract:
Phosphorylation and dephosphorylation of Tyr-530 in human c-Src (Tyr-527 in avian c-Src) is critical in regulating c-Src kinase activity. So far, it has not been possible to distinguish the active and inactive forms in vivo. We now report a new monoclonal antibody that selectively recognizes the active form of c-Src. This antibody, termed clone 28, recognized a region adjacent to Tyr-530 (Q529YQP532) in the C-terminal regulatory domain of c-Src, and its binding was hindered by phosphorylation of this tyrosine as determined by peptide competition assay. Combined immunoprecipitation/Western blotting revealed that clone 28 reacted with a 60-kDa protein that was precipitated by mAb 327, a well known monoclonal antibody against v-Src and c-Src. Cyanogen bromide cleavage and two-dimensional tryptic maps confirmed that clone 28 was specific for the active form (Tyr-530 not phosphorylated), whereas mAb 327 recognized the inactive form (Tyr-530 phosphorylated) as well as the active form. Clone 28 selectively immunoprecipitated the active form and augmented its kinase activity. Preabsorption experiments revealed that clone 28 could not completely immunoprecipitate the mAb 327 binding 60-kDa protein in either an in vitro or an in vivo phosphorylation system. These observations, taken together, strongly suggest the existence of multiple forms of c-Src as proposed by Cooper and Howell (1993) (Cooper, J. A., and Howell, B. (1993) Cell 73, 1051-1054). Using clone 28, we demonstrated a distinct localization of the active form of c-Src within cultured normal fibroblast cells. In liver tissue sections, we also examined the distribution of the active form in embryonic mice. Megakaryocytes were strongly stained, in contrast to completely negative immunoreactivity in hepatocytes, reticulocytes, and granulocytes. This result provides the first direct evidence that c-Src is highly activated in platelets.
Insights
A new antibody, clone 28, distinguishes the active form of c-Src kinase in vivo. This discovery enables visualization of active c-Src in cells and tissues, revealing its activation in platelets.
Area of Science:
- Cellular Biology
- Molecular Biology
- Biochemistry
Background:
- Regulation of c-Src kinase activity is crucial and involves phosphorylation/dephosphorylation of Tyr-530.
- Distinguishing between active and inactive c-Src forms in vivo has been a significant challenge.
- Previous methods could not differentiate c-Src states, limiting in vivo functional studies.
Purpose of the Study:
- To develop a method for distinguishing active from inactive forms of c-Src kinase in vivo.
- To characterize a novel monoclonal antibody that selectively recognizes the active form of c-Src.
- To investigate the cellular and tissue distribution of the active c-Src form.
Main Methods:
- Development and characterization of a new monoclonal antibody, clone 28, specific for active c-Src.
- Peptide competition assays to determine antibody binding specificity.
- Immunoprecipitation and Western blotting using clone 28 and mAb 327.
- Cyanogen bromide cleavage and two-dimensional tryptic mapping.
- Immunofluorescence microscopy in cultured cells and immunohistochemistry in mouse tissues.
Main Results:
- Clone 28 selectively recognizes the active, non-phosphorylated Tyr-530 form of c-Src.
- mAb 327 recognizes both active and inactive (phosphorylated Tyr-530) forms of c-Src.
- Clone 28 demonstrates distinct localization of active c-Src in fibroblasts and highlights high activation in megakaryocytes within embryonic mouse liver tissue.
Conclusions:
- Clone 28 provides the first tool to specifically detect the active form of c-Src in vivo.
- The findings support the existence of multiple c-Src forms, as previously hypothesized.
- Direct evidence shows high c-Src activation in platelets (megakaryocytes), opening new avenues for research.